A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease

Terminated

• Conditions: Parkinson Disease

• Registration Number: NCT04893083
• Lead Sponsor: Neuron23 Inc.

Brief Summary

This study aims to collect, analyze and preserve biospecimens from patients with or without LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-05-12
• Study First Submitted QC: 2021-05-18
• Study First Posted: 2021-05-19
• Study Start: 2021-06-28
• Primary Completion: 2023-06-30
• Study Completion: 2023-09-22
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-26
• Last Update Posted: 2023-10-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

• Male or female ≥40
• Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria and modified Hoehn and Yahr Stage I, II, or III;
• Willing to undergo genetic testing for neurologic genotyping panel; -If being treated for Parkinson's disease, must have been on a stable dose of anti- Parkinson's disease medications for a minimum of 30 days prior to Day 1;
• If taking statins, fibrates, antipsychotic or anticonvulsant medications at Day 1, must have been on a stable dose for a minimum of 30 days, and are not likely to require a change in dosage for the remainder of the study;

Exclusion Criteria

• Any major medical illness or unstable medical condition within 6 months of screening that, in the opinion of the Investigator or Sponsor, may interfere with the subject's ability to comply with study procedures or abide by study restrictions.
• Diagnosis of a significant central nervous system disease other than Parkinson's disease(eg, Huntington's disease, frontotemporal dementia, multi-infarct dementia, normal pressure hydrocephalus, multiple system atrophy, progressive supranuclear palsy, drug- induced parkinsonism, Alzheimer's disease)
• History of stroke;
• History of epilepsy or seizure disorder other than febrile seizures as a child, or any seizure or unexpected loss of consciousness (eg, syncope) within 6 months prior to Day 1;
• History of traumatic brain injury with residual neurological deficit; -If taking anti-Parkinson's disease medication(s)and are likely to require a change in anti- Parkinson's disease medication(s) during the study;
• Known active infectious disease or active infections within 30 days prior to Day 1;
• Any vaccination within 21 days prior to Day 1;
• Currently taking, or planning to take, anti-coagulant medications or antiplatelet medications during the study;
• Allergy to Lidocaine (xylocaine) or its derivatives or any other LP contraindications;
• Any other condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study; -Any systemic glucocorticoids taken within 14 days prior to Day 1 or non-steroidal anti- inflammatory drugs taken within 4 days prior to Day 1;
• Received blood products within 30 days prior to Day 1;
• Donated blood within 30 days prior to Day 1.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genetic Marker	1 day	Test for LRRK2 mutations in Parkinson disease patients; identifying patients with potential genetic modifiers

Trial Locations

Locations (8)

Tel Aviv Medical Center; 🇮🇱 Tel Aviv, Israel

Universite Laval; 🇨🇦 Québec City, Quebec, Canada

McGill University; 🇨🇦 Montréal, Canada

Sheba Tel HaShomer; 🇮🇱 Ramat Gan, Israel

Rocky Mountain Movement Disorders Center; 🇺🇸 Englewood, Colorado, United States

Evergreen Health; 🇺🇸 Kirkland, Washington, United States

Assistance Publique - Hospitaux de Paris; 🇫🇷 Paris, France

Quest Research Institute; 🇺🇸 Farmington Hills, Michigan, United States